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Introduction
Blood neutrophil levels are tightly con-
trolled. Under normal homeostatic conditions,
bone marrow neutrophil production (granu-
lopoiesis) closely matches neutrophil elimina-
tion, thus resulting in stable numbers of circu-
lating neutrophils (1). Although a homeostatic
regulatory mechanism has been suspected to
exist for over 15 yr (2,3), the cytokine cascade
regulating neutrophil production was only dis-
covered recently (1). IL-23, a heterodimeric
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cytokine sharing one subunit with IL-12, is pro-
duced in response to environmental stimuli by
macrophages and dendritic cells (DCs) in gut-
associated lymphatic tissue and stimulates IL-
17A production by a small subset of T cells
(0.2% of all splenocytes in normal C57BL/6
mice), which in turn leads to elevated G-CSF
production and enhanced granulopoiesis (4,5).
When enough neutrophils reach their various
target tissues and become apoptotic, they are
phagocytosed by macrophages and DCs, lead-
ing to a downregulation of IL-23 production by
these cells (1). Thus, a closed-loop feedback is
established that regulates neutrophil produc-
tion, similar to the way erythropoietin levels in
response to hypoxia regulate erythrocyte home-
ostasis (2,6). This review is focused on the IL-
17A-producing T (Tn) lymphocytes that play
an essential role in neutrophil homeostasis and
altered neutrophil production in disease.
IL-17A and Its Receptor
IL-17A is a member of the IL-17 family of
cytokines that currently consists of IL-17A,
B, C, D, E, and F, (7–12). IL-17A, also known
as cytotoxic T-lymphocyte-associated anti-
gen 8, is a homodimeric glycoprotein of 155
amino acids (aa) (Fig. 1A) (7,13). Human IL-
17F is closely related to IL-17A with 61% aa
identity. Detailed structural analysis of IL-
17F has revealed that it is a member of the
cysteine knot superfamily sharing similarities
with nerve growth factor (Fig. 1B) (14). IL-
17A is secreted by activated T cells and is
highly conserved between species with a 61%
aa identity between human and mouse. IL-
17A is detectable in blood serum, synovial
fluid, and tissue culture supernatants by com-
mercial ELISA assays (1,13,15,16).
The receptor for IL-17A is interleukin 17
receptor (IL-17R). Human IL-17R is an 866 aa
type I transmembrane glycoprotein (Fig. 1C)
(17,18). IL-17R is highly conserved between
species with a 72% aa identity between human
and mouse (17). Currently, all secreted IL-17A
is believed to be biologically active at its recep-
tor, to which it binds with relatively low affin-
ity KD 72 nM (13,14). Five additional receptors,
IL17RB–E, have also been described which are
ubiquitously expressed (19). A recent study by
Kramer et al. (20) elegantly demonstrated that
IL-17R exists in a preassembled multimerized
form on the plasma membrane and the binding
of its ligand (either IL-17A or IL-17F) induced
a conformational change in the receptor as
determined by a reduction in fluorescence res-
onance energy transfer (FRET) levels. Interest-
ingly, the aa sequence of IL-17R family does
not exhibit homology with any other cytokine
receptors in either the extracellular or intracel-
lular signaling motifs (17). IL-17R signaling
varies according to cell type. In immortalized
human bronchial epithelial cells (16HBE) IL-
17 signals through P38 and extracellular signal
regulation kinase (ERK) mitogen activated pro-
tein (MAP) kinase pathways to induce IL-6 and
IL-8 release, but not through protein kinase C
(PKC) or phosphoinositide 3 (PI3) kinase (21).
In fibroblast-like synoviocytes isolated from the
diseased synovium of rheumatoid arthritis
patients, IL-17 also activates the MAP kinase
pathway through P38 and ERK phosphoryla-
tion as well as activating the mobilization of the
transcription factor nuclear factor kappa B
(NFκB) (22). Upstream of the MAP kinases,
IL-17R has been demonstrated to signal via the
signal transducer TNF receptor associated
factor 6 (TRAF6; through which IL-1β signals)
but not TRAF2 (through which TNF-α signals).
Indeed, it has been speculated that the intracel-
lular signaling of IL-17R is similar to that of the
Toll-like /interleukin-1 receptor pathways.
TRAF6 knockout mice have been generated,
however they do not survive into adulthood and
there are no reports on circulating neutrophil
numbers in these mice, although immature B
cell numbers were reduced (23,24) Both NFκB
and activator protein-1 (AP-1) have binding
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sites within the promoter regions of IL-17A and
many other proinflammatory genes. IL-17A
regulates a variety of inflammatory cytokines
(i.e., IL-6), chemokines (i.e., CCL2, CXCL1,
CXCL6, and CXCL8), colony stimulating fac-
tors (i.e., G-CSF and GM-CSF), and matrix
metalloproteinases (MMP’s) (13,19,25).
IL-17A Producing Cells 
in Normal Mice and Humans
Several groups have recently reported that
IL-17A is produced by CD4 T cells following
stimulation by the newly discovered cytokine
IL-23 (1,25–28). This discovery is based on
intracellular staining for IL-17A after block-
ing exocytosis of proteins by brefeldin A or
similar drugs. IL-17A-producing CD4 T cells
have been called Th17 (25,28), ThIL-17
(27,29), or Th1β (Mark Kaplan, unpublished)
to emphasize their role as helper T cells (Th)
with a unique function distinct from Th1 and
Th2. Indeed, gene expression analysis of
unfractionated splenocytes showed that
splenocytes stimulated with IL-23, the cog-
nate inhancer of IL-17A producing T cells,
have a distinct gene expression profile quite
unlike splenocytes stimulated with the Th1
cytokine IL-12 (27).
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Fig. 1. A schematic diagram of human IL-17A and its cognate receptor: IL-17A is a homodimer with
(A) one N-linked glycosylation site and six conserved cysteine residues. As yet, only the crystal structure
for IL-17F has been described with the ribbon trace (B) presented here. The receptor for hIL-17A and F (C)
is a type I transmembrane glycoprotein, with an extracellular domain containing seven N-linked glycosyla-
tion sites with potential structural similarity to a tandem fibronectin 3 like domain. IL-17R also has a car-
boxy proximal transmembrane domain and a long cytoplasmic tail (81). Signaling via the JNK kinase and
MAP kinase pathways occurs via TRAF6.
The CD4+ T cell population (“Th17 cells”)
constitutes only a minor fraction of IL-17A-
producing T cells in normal mice (1). In
C57BL/6 mice, most IL-17A-producing cells
are found in the mesenteric lymph node (1).
There and in the spleen most (50–60%) IL-
17A-producing cells are γδ T cells (0.2% of
all splenocytes) that do not express CD4 (Fig.
2). Of the remaining IL-17A-producing T
cells, αβ CD4+ Th17 cells, account for about
0.1% of all splenocytes and NKT cell-like
with a restricted T cell receptor repertoire
(preference for Vβ8) account for 0.01%. IL-
17A has also been reported to be expressed at
the mRNA level in neutrophils (30) and
secreted albeit at low levels by CD8+ T cells
(7,25,31). Current evidence suggests that
most if not all of the biologically relevant IL-
17A production is restricted to T cells, as nude
mice (C57BL/bnu/nu) express no detectable
IL-17A protein (Stark, Burcin, and Ley
unpublished data). Furthermore, nude and
SCID immunodeficent mice are neutropenic;
however, thymus grafts into nude mice nor-
malizes the circulating neutrophil numbers to
the same levels as wild-type BALB/c mice
(32). Conversely, overexpression of IL-17A in
mice causes splenomegaly, increased white
blood cell counts, and a 10-fold increase in
circulating neutrophil numbers with G-CSF
levels transiently increasing for 24 h after ade-
novirus-mediated gene transfer (33).
In mice lacking neutrophil adhesion mole-
cules, chemokines, or chemokine receptors
(Fig. 2B), the number of Tn cells is grossly ele-
vated. The proportion of γδ vs αβ (NKT-like)
vs CD4+ αβ T cells is altered in a systematic
fashion. While γδT cells are the most abundant
IL-17A producers in wild-type mice, the αβ
NKT-like cells are more abundant in the
severely compromised mice with very high
neutrophil counts. This suggests that IL-17A
production is tightly regulated, and that the
NKT-like cells are recruited to produce more
IL-17A under emergency conditions. Surpris-
ingly, both the NKT-like cells and the γδT cells
have not been as thoroughly investigated as the
CD4+ Th17 cells, although the former account
for the majority of all IL-17A-producing cells.
In wild-type mice, all IL-17A-producing T
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Fig. 2. Frequency of Tn cells in the spleen of wild-type and adhesion molecule–deficient mice. The per-
centage of IL-17-producing Tn cells as percentage of an splenocyte varies between adhesion molecule–defi-
cient models (A); however, there is a significant increase in Tn cell numbers in all models compared to the
wild-type mice. Data displayed on log scale. (B) Fractionation of Tn cells into γδ T cells (black), NKT-like
T cells (white) and αβ CD4 T cells (grey). IL-17A production varies among adhesion molecule–deficient mice
and the more neutrophilic mice have a larger fraction of IL-17A producing NKT-like cells compared to wild
type.
cells express CD69 and high levels of CD44,
about half of them express CD25 and αE inte-
grin (CD103), and all are L-selectin (CD62L)
negative (Fig. 3).
CD18–/– mice lack all four β2 integrins and
have high levels of IL-17A in the plasma (68
± 30 pg/mL) (5) and develop chronic dermati-
tis with extensive facial and submandibular
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Fig. 3. Characterization of Tn cells in the spleen of healthy and severely neutrophilic mice. Splenocytes
from either (A) CD18–/– or (B and C) wild-type mice were stimulated for 5 h with PMA (10 ng/mL) and ion-
omycin (500 ng/mL) in the presence of GolgiStop, then stained for both surface antigens and intracellular
IL-17. Histogram plots (C) were gated on all IL-17 positive cells for analysis of activation markers repre-
sented by solid lines. The shaded area represents corresponding isotype control.
skin erosions. Their phenotype includes
elevated neutrophil counts, increased immuno-
globulin levels, lymphadenopathy, spleno-
megaly, and abundant plasma cells in skin,
lymph nodes, gut, and kidney (34). One intrigu-
ing possibility is that the intensity and incidence
of the inflammatory phenotype is com-
mensurate with the high levels of IL-17A. In a
transient IL-17A overexpression study, aden-
ovirus-mediated gene transfer of the murine IL-
17 cDNA targeted to the liver resulted in a
transiently transgenic phenotype with a 10-fold
rise in the absolute neutrophil count, a doubling
of spleen size, and an increase in frequency of
highly proliferative potential colonies, CFU-
granulocyte- macrophage and CFU-granulo-
cyte-erythrocyte-megakaryocyte-monocyte
(33). Inflammatory disease was not reported.
Schwarzenberger et al. measured mIL-17
plasma levels using a bioassay based on IL-
17A-stimulated IL-6 release from 3T3 fibrob-
lasts. They expressed IL-17A levels in units,
which are not directly convertible to pg/mL.
However, the transient transgenics showed a
10-fold increase of plasma IL-17A above
normal non-transgenic or vector control mice,
suggesting that the level of IL-17A was roughly
similar in the transient transgenics and CD18–/–
mice (5,33). Both observations make it clear
that murine IL-17A is a cytokine that can stim-
ulate granulopoiesis in vivo, but also has proin-
flammatory effects.
Even higher levels of plasma IL-17A are
reached in mice lacking both CD18 and E-
selectin (120 ± 30 pg/mL). These mice do not
reach adulthood and have 55-fold elevated
blood neutrophil counts (35). Since the mice
died at weaning, the inflammatory phenotype
was not fully investigated, but ulcerative der-
matitis and neutrophil accumulation in the
lungs were observed, which may be related to
the early lethality (35). In mice lacking CD18
and P-selectin (CD18–/–P–/–), IL-17A levels
were higher still at 215 pg/mL. These mice
did not gain weight after weaning and died
between 10 and 30 wk of age (35). Some
CD18–/–P–/– mice developed ulcerative der-
matitis and conjunctivitis. They also showed
severe lung pathology with interstitial neu-
trophil accumulation, hemorrhage, and exu-
date. The lungs were also colonized with
bacteria (10 of 16 analyzed), as were 10 of 16
livers and 4 of 14 spleens (36). In adhesion
molecule–deficient mice, it is impossible to
know whether the inflammatory disease is
secondary to the elevated IL-17 levels or
caused by the bacterial colonization that
remains unchecked because of the severe
defect in neutrophil migration. Interestingly,
mice lacking CD18 and IL-17R do not survive
past the age of 3 mo (Stark, Bruce, and Ley,
unpublished observations), suggesting that
elevated IL-17A levels in CD18–/– mice serve
an important compensatory role.
IL-23 and Its Receptor
In vitro, the combination of IL-6 and trans-
forming growth factor β1 (TGF-β1) can
induce IL-17A production in naive CD4 T
cells (37). IL-17A production is greatly
enhanced when IL-23 binds its cognate recep-
tor, IL-23R, on activated memory T cells
(26). IL-23 is a heterodimer composed of the
unique IL-23p19 chain linked by a disulfide
bridge to the common p40 chain (also known
as IL-12p40) that it shares with IL-12 (Fig.
4A) (38). Until recently, measuring p40 was
thought to be sufficient to detect IL-12, and
many older publications refer to IL-12 when
p40 is actually measured (39,40). Knockout
mice lacking p40 are deficient for both IL-12
and IL-23, while p35 knockout mice lack only
IL-12 and p19 knockout mice lack only IL-23
(29,41,42). Human IL-23 is a 189 aa polypep-
tide (196 aa in mouse) similar in structure to
IL-12p35 (Fig. 4B) with a 74% aa identity
between human and mouse (38). Interest-
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ingly, purified p19 has no biological activity
without forming a heterodimer with p40 and
it must be co-expressed with p40 to be effi-
ciently secreted from cells (38).
The cDNA for IL-23 is expressed in various
tissues and highly expressed in macrophages,
DCs derived from peripheral blood monocytes
(but not bone marrow–derived DCs) and polar-
ized Th1 cells (38). In DCs and macrophages,
IL-23 is secreted in high concentrations upon
stimulation by tumor necrosis factor-α (TNF-
α), Toll-like receptor (TLR) agonists such as
bacterial lipopolysaccharide (LPS) and by
CD40 ligation by CD40L as well as in smaller
quantities by Fas ligand (38,43–46). Activated
macrophages and DCs are able to secrete IL-12
and IL-23 simultaneously (38). However, these
cells may also be able to selectively produce
either cytokine, although the putative switching
mechanism is not known. Recent studies have
shown a role for IL-23 in autoimmune diseases,
such as experimental autoimmune encephalo-
myelitis (EAE) and collagen-induced arthritis
mouse models (27,42). Moreover, the overex-
pression of p19 in transgenic mice not only
drastically increases neutrophil and lymphocyte
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Fig. 4. A schematic diagram of the IL-23p40/p19 complex and its cognate receptor: IL-23 is a het-
erodimer comprised of (A) two subunits; the common p40 subunit that it shares with IL-12 and the unique
p19 subunit. The receptor for IL-23 forms a heterodimer (B) comprised of the IL-12β1R and the IL-23R. Both
receptor subunits consist of an extracellular N-terminal Ig-like domain, two cytokine receptor domains, a
transmembrane domain, and a cytoplasmic tail. The cytoplasmic tail of hIL-23R contains seven tyrosine
residues through which it signals via a number of well-defined signaling pathways including Stat 1, 3, 4, and
5, SRC homology 2, SHP2 and JNK kinase (48).
numbers but also results in multiorgan inflam-
mation and premature death (47). The pheno-
type of these mice is more severe than that of
IL-17A overexpressing mice (33).
The p19p40 heterodimer has one known
receptor called IL-23 receptor (IL-23R). Initial
investigations found that IL-23 could bind to
IL-12Rβ1 (but not IL-12Rβ2) and activate Stat
4; however, levels of activation were low com-
pared to IL-12 and therefore a unique receptor
for IL-23 was sought (38). Parham et al. were
the first group to describe and characterize the
unique IL-23R and its signaling capabilities
from cDNA libraries (48). IL-23R is highly
conserved between species with a 66% aa
identity between human and mouse. The cyto-
plasmic tail of hIL-23R contains seven tyrosine
residues, three of which are Src homology 2
domain binding sites. Src homology 2 phos-
phatase 2 (SHP2), signal transducer and acti-
vator of transcription 1 (stat1), stat3, and stat4
also have potential binding sites within the
cytoplasmic tail of IL-23R and the tyrosine
kinase Janus activated kinase 2 (Jak2) is con-
stitutively associated with the cytokine recep-
tor (Fig. 4B) (48). Thus, the binding of IL-23
to its cognate receptor complex results in the
tyrosine phosphorylation of Jak2 and tyrosine
kinase 2 (Tyk2) as well as stat1, stat3, stat4,
and stat5, which translocate to the nucleus (48).
IL-23R is expressed on a small subset of T cells
(Th1 and Th0), DCs, activated macrophages,
and NK cells (48). Current evidence suggests
that IL-23 is the primary regulator of IL-17A
release from memory T cells, although in vitro
assays have demonstrated that these cells are
capable of producing IL-17A, albeit in small
quantities, upon incubation with conditioned
medium from p40–/– DC (31). Thus, IL-17A
levels may be regulated by other soluble or
cell-mediated factors. IL-15 has been shown to
induce IL-17A production in peripheral blood
and synovial fluid mononuclear cells and CD4
T cells isolated from the spleen (49,50).
G-CSF, Granulopoiesis, and Regulation 
of Blood Neutrophil Counts
An important downstream effect of IL-17A
is the production of granulocyte colony-stim-
ulating factor (G-CSF) (5). Human G-CSF is a
174 aa peptide with five conserved cysteine
residues (2). The mouse homolog for G-CSF is
termed colony stimulating factor 3 (granulo-
cyte) and shares a 75% aa identity with human
G-CSF (51). G-CSF is produced by bone
marrow stromal cells of monocyte/macrophage
lineage as well as vascular endothelial cells,
fibroblasts, and mesothelial cells and its
expression is tightly regulated. G-CSF binds a
single known receptor, G-CSFR, which is
expressed on all neutrophil precursor cells in
the bone marrow with the mature neutrophil
expressing the highest number of receptors on
its surface (2). Human G-CSFR is a homod-
imer, consisting of an extracellular domain
with one NH2-terminal Ig like domain, a cys-
teine-rich double-loop domain, four fibro-
nectin type III domains, a transmembrane
domain, and an intracellular domain (52).
Upon the binding of G-CSF to its receptor, it
causes the proliferation, differentiation, and
activation of granulocyte precursors (2). Inter-
estingly, serum G-CSF levels are significantly
raised in adhesion receptor–deficient mice and
levels positively correlate with neutrophilia
(5). In addition to this, antibody blockade of G-
CSF reduces circulating neutrophil levels
within these murine models but does not affect
IL-17 levels leading to the conclusion that G-
CSF is acting downstream of IL-17 (1,5,53).
The Neutrostat: A Homeostatic 
Feedback Loop
Neutrophil production is regulated by G-
CSF, which in turn is induced by IL-17A pro-
duced by neutrophil-regulatory T cells (Tn
cells). Most Tn cells express γδ TCR, while a
smaller group express αβ TCR with preferred
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Vβ8 usage and no CD4 expression, and the
remainder are classical CD4 αβ T cells. IL-
17A production in these cells requires IL-23,
which is provided by activated DCs and
macrophages. The constitutive expression of
p40 subunit in the terminal ileum and the cor-
responding high expression of IL-23 is prob-
ably triggered by signals generated from the
local bacterial flora of the terminal ileum
stimulating Toll-like receptors and other pat-
tern recognition receptors on DCs (4,54).
This is supported by the observation that
germ-free mice have reduced p40 expression
compared to healthy mice, and germ-free rats
exhibit lower blood neutrophil numbers (4,55)
The neutrostat feedback loop (Fig. 5) is closed
by neutrophils trafficking to tissues like the
gut, skin, and mucosal membranes, where
they become apoptotic and are taken up by
resident phagocytes (1). Both macrophages
and DCs curb their IL-23 production after
uptake of apoptotic neutrophils (or other
apoptotic cells) (1).
As compared to other physiologic feedback
loops, the neutrostat regulatory loop is rather
long, i.e., it involves many stations. This sug-
gests that, in addition to the main pathway
through IL-23, IL-17A, and G-CSF described
here, other cytokines must exist that may
modulate this loop. Indeed, G-CSF can be
induced by a variety of cytokines (Table 1).
While we know today that efficient IL-17A
production requires IL-23 or IL-15, it is only
a matter of time until other modulators of IL-
17A are discovered (37). Similarly, the full
range of stimuli that induce IL-23 are not yet
known. However, the phagocytosis of apop-
totic cells seems to be a major mechanism
reducing IL-23 expression and secretion (1).
It is informative to look at the phenotype of
the knockout mice lacking cytokines and
cytokine receptors involved in the neutrostat
pathway. G-CSF and G-CSFR knockout mice
have almost the same phenotype and show an
80% reduction of blood neutrophil counts
(56,57). This would be expected of knocking
out a very proximal regulator of neutrophil
production. By contrast, IL-17R knockout
mice have only a 40% reduction in blood neu-
trophil counts, consistent with the more distal
role of IL-17R in the loop (53). This suggests
that other stimuli might compensate and
induce some G-CSF. Although a IL-17-defi-
cient mouse has been generated, the circulat-
ing neutrophil numbers were not reported
(58). The IL-23p19 knockout mouse has been
reported to have normal numbers of periph-
eral blood leukocytes, although neutrophil
numbers were not specified (59). This is con-
sistent with the notion that IL-23 is quite
upstream and other cytokines may compen-
sate for the absence of IL-23. The IL-23R
knockout mouse has not been reported yet.
Knocking out genes that encode for neu-
trophil-trafficking molecules has effects
opposite from knocking out cytokines or
cytokine receptors as such interventions
break the neutrostat feedback loop. Thus,
interfering with the extravasation of neu-
trophils into tissues leads to elevated neu-
trophil counts (Table 2), because the
neutrophils cannot reach their target tissues
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Table 1. Agents Regulating G-CSF Expression 
and Secretion
Modulators of G-CSF expression
Epidermal growth factor (68)
Interleukin-1 (69–71)
Interleukin-3 (71,72)
Interleukin-4 (71,73,74)
Interleukin-10 (71)
Interleukin-17A (1,5)
Tumor necrosis factor-α (TNF-α) (71,75–77)
Bacterial lipopolysaccharide (LPS) (71,72,76)
Granulocyte/macrophage colony stimulating factor
(GM-CSF) (78)
Interferon-γ (77,78)
Phorbol 12-myristate 13-acetate (PMA) (72,75)
effectively. This leads to elevated IL-23, IL-
17A, and G-CSF levels, which drives ele-
vated neutrophil production and blood counts
(1,5). Support for this concept comes from
mixed chimeric mice reconstituted with bone
marrow from CD18 knockout mice and wild-
type littermates at a 1:1 ratio (5,60). CD18
knockout mice have 50-fold elevated neu-
trophil counts (34). By contrast, mixed
chimeric mice, in which half of the neu-
trophils lack CD18 integrins, have normal
neutrophil counts (5,60). This shows that
neutrophil production is downregulated when
(some) neutrophils reach their target tissues
effectively, apoptose, and become phagocy-
tosed. Indeed, injecting normal wild-type
neutrophils into CD18 knockout mice tran-
siently corrects the neutrophilia and brings
down the IL-17A and G-CSF levels (1).
Remarkably, in the mixed chimeric mice, the
ratio of knockout and wild-type neutrophils
reflects the number of transplanted bone
marrow cells (5). If CD18 knockout neu-
trophils simply accumulated in the circula-
tion because they cannot emigrate, a higher
proportion of knockout than wild-type cells
would be expected.
Anti-inflammatory Effect 
of Phagocytosing Apoptotic Cells
Phagocytosis of apoptotic cells has strong
anti-inflammatory effects on professional
phagocytes some of which are mediated by
TGF-β (61–65). Among other cytokines, the
secretion of IL-12 (66) and IL-23 is drasti-
cally reduced after uptake of apoptotic cells
(1). The mechanism by which apoptotic cells
curb the inflammatory response is poorly
understood. It is known that this type of
phagocytosis is independent of complement
and of β2 integrins on the phagocyte (61).
Phosphatidylserine (PS) in the outer leaflet of
the apoptotic cell is thought to play an impor-
tant role, but the pathway by which PS shuts
down inflammatory responses remains to be
explored (67).
Conclusions and Future Directions
The discovery of a homeostatic regulation
mechanism that controls neutrophil produc-
tion invites investigations into many of the
details of its regulation. The most abundant
neutrophil regulatory Tn cells are γδ T cells,
followed by αβ NKT-like T cells and αβ
CD4 T cells. Surprisingly, only the latter
have received some attention regarding their
regulation, maturation, trafficking, and pre-
cise lineage and development. The gene
expression profiles of the three Tn cell sub-
sets have not been investigated, but would
be very informative. Progress in this area
has been hampered by the low number of
cells and the difficulty in recovering mRNA
after intracellular staining. IL-23 is needed
to make IL-17A, but it is not sufficient. It is
unknown how phagocytes “decide” to make
IL-12 or IL-23. It is likely that Tn cells play
important roles in diseases, in fact, this
has already been shown for the subset of
Th17 cells in EAE and RA. Other downstream
effects of IL-17A must be investigated.
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Table 2. Peripheral Blood Neutrophil Counts in Wild-
Type and Adhesion Molecule Deficient Murine Modelsa
Peripheral blood 
Murine models neurophil counts
Wild type †1.3 ± 0.1
CD18–/– †22.6 ± 1.6**
E/P–/– †27.0 ± 2.0**
E/P/L–/– 7.0 ± 3.2* (79)
LFA–/– †4.6 ± 0.3**
Core2–/– 2.4 ± 0.4 (80)
a A comparison between adhesion deficient mice and wild
type mice. Data presented as neutrophil numbers x 103/µuL ±
SEM (*p < 0.05, **p < 0.0001 by unpaired Student’s t test).
† M.A. Stark, T. Burcin, and K. Ley unpublished observa-
tions. E/P, E- and P-selectin; E/P/L, triple selectin; core2,
core2GlcNAc transferase.
Candidates include IL-6, CCL2, and
CXCL8, but more downstream cytokines
probably remain to be discovered. Tn cells
are probably as important as Th1 and Th2
cells, and a rapid increase in the number of
publications investigating these cells can be
expected.
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